These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31265867)

  • 21. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis.
    Vardakas KZ; Voulgaris GL; Samonis G; Falagas ME
    Int J Antimicrob Agents; 2018 Jan; 51(1):1-9. PubMed ID: 28669836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
    Leuppi-Taegtmeyer AB; Decosterd L; Osthoff M; Mueller NJ; Buclin T; Corti N
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colistin loading dose enhanced antimicrobial activity for in vivo mouse thigh infection model with Pseudomonas aeruginosa with highly antimicrobial resistant.
    Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
    J Infect Chemother; 2017 Mar; 23(3):189-192. PubMed ID: 27856109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
    Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI
    Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
    Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
    Ribera A; Benavent E; Lora-Tamayo J; Tubau F; Pedrero S; Cabo X; Ariza J; Murillo O
    J Antimicrob Chemother; 2015 Dec; 70(12):3357-65. PubMed ID: 26419763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
    Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
    Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients.
    Hachem RY; Chemaly RF; Ahmar CA; Jiang Y; Boktour MR; Rjaili GA; Bodey GP; Raad II
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1905-11. PubMed ID: 17387153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients.
    Mastoraki A; Douka E; Kriaras I; Stravopodis G; Manoli H; Geroulanos S
    Surg Infect (Larchmt); 2008 Apr; 9(2):153-60. PubMed ID: 18426347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.
    Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G
    Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
    Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
    Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates.
    Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R
    Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria.
    Zhu C; Schneider EK; Wang J; Kempe K; Wilson P; Velkov T; Li J; Davis TP; Whittaker MR; Haddleton DM
    J Control Release; 2017 Aug; 259():83-91. PubMed ID: 28174100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli].
    Fica C A; Céspedes J I; Gompertz G M; Jalón V M; Sakurada Z A; Sáez L E
    Rev Chilena Infectol; 2007 Oct; 24(5):360-7. PubMed ID: 17989839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use.
    Daikos GL; Skiada A; Pavleas J; Vafiadi C; Salatas K; Tofas P; Tzanetou K; Markogiannakis A; Thomopoulos G; Vafiadi I; Petrikkos G
    J Chemother; 2010 Jun; 22(3):175-8. PubMed ID: 20566422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Practical guideline for the use of colistin].
    Dijkmans AC; Wilms EB; Kamerling IM; Birkhoff W; van Nieuwkoop C; Verbrugh HA; Touw DJ
    Ned Tijdschr Geneeskd; 2014; 158():A7445. PubMed ID: 25322351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.